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ttp://dx.doi.org/10.1016/j.jmoldx.2014.06.004Ongoing cancer genome characterization studies continue to elucidate the spectrum of genomic
abnormalities that drive many cancers, and in the clinical arena assessment of the driver genetic
alterations in patients is playing an increasingly important diagnostic and/or prognostic role for
many cancer types. However, the landscape of genomic abnormalities is still unknown for less
common cancers, and the inﬂuence of speciﬁc genotypes on clinical behavior is often still unclear. To
address some of these deﬁciencies, we developed Proﬁle, a prospective cohort study to obtain
genomic information on all patients at a large tertiary care medical center for cancer-related care. We
enrolled patients with any cancer diagnosis, and, for each patient (unselected for cancer site or type)
we applied mass spectrometric genotyping (OncoMap) of 471 common recurrent mutations in 41
cancer-related genes. We report the results of the ﬁrst 5000 patients, of which 26% exhibited
potentially actionable somatic mutations. These observations indicate the utility of genotyping in
advancing the ﬁeld of precision oncology. (J Mol Diagn 2014, 16: 660e672; http://dx.doi.org/
10.1016/j.jmoldx.2014.06.004)Supported by the Dana-Farber Cancer Institute and NIH grant R33
CA155554.
Disclosures: L.A.G. has received consulting fees or other remuneration
from and also holds stock or bond holdings in Foundation Medicine.Within the past decade the application of genome interro-
gation technologies to patient samples has greatly expanded
our understanding of the spectrum of genomic alterations
that underpin cancer initiation and progression and those
events that contribute to the evolution of cancer and the
emergence of resistance to targeted therapies. Studies such
as the Cancer Genome Atlas (http://cancergenome.nih.gov)
and the International Cancer Genome Consortium1 have
comprehensively characterized >20 cancer types. Such
studies have conﬁrmed the incidence of many known on-
cogenes and tumor suppressor genes but have also identiﬁed
hitherto unrecognized genes and pathways recurrently
altered in cancers.
In parallel with research endeavors, information gleaned
from these studies has been translated to the molecular
diagnostics arena to develop clinical tests that can detect
somatic alterations in speciﬁc cancer types. Often, thesestigative Pathology
.clinical tests take the form of a gene- or alteration-targeted
approach and can be used for diagnostic purposes (eg,
BRAF testing to distinguish between subtypes of thyroid
papillary carcinoma), prognostic indications (NPM1 and
FLT3 testing in acute myeloid leukemia),2,3 predicting
response to a targeted therapy (EGFR mutation analysis as
an indicator for therapeutic response in metastatic non-small
cell lung cancer), or detecting resistance to a targeted agent
(ABL1 kinase domain mutational analysis for imatinib
(Gleevec)-resistance in patients with chronic myelogenous
leukemia). Moreover, clinical guidelines for some cancers
encourage a sequential testing process, as exempliﬁed by the
Enterprise-Wide Cancer Sequencingtesting guidelines for non-small cell lung cancer by the
College of American Pathologists, International Association
for the Study of Lung Cancer, and the Association for
Molecular Pathology.4 Completing these tests is not
necessarily a cost-effective exercise and uses substantial
amounts of nucleic acid material, which may be limiting for
many patients with cancer. In addition, expanding catalogs
of cancer mutations challenge that these events are tissue
speciﬁc or occur in isolation. For example, activating BRAF
mutations have been described in >50% of papillary thyroid
carcinomas5 and cutaneous melanomas but also at a lower
frequency in lung cancer,6 colorectal adenocarcinoma,7
pediatric low-grade glioma,7 and multiple myeloma.8 These
mutant BRAF proteins are potential targets for RAF in-
hibitors,9 and clinical trials have conﬁrmed the utility of
targeted therapies in some of these instances.10,11 An ever-
expanding number of other targetable proteins, including
phosphatidylinositol-4, 5-bisphosphate 3-kinase, catalytic
subunit a (PIK3CA), epidermal growth factor receptor
(EGFR), and v-erb-b2 avian erythroblastic leukemia viral
oncogene homolog 2 (ERBB2), are aberrant in multiple
cancer types.7,12,13 Moreover, interrogating the mutational
status of multiple genes has found clinical utility in some
settings; for example, acquired resistance to EGFR tyrosine
kinase inhibitors (TKIs) in non-small cell lung cancer can be
due to the EGFR T790M mutation,MET gene ampliﬁcation,
or mutation of PIK3CA.14
A more rational approach to individualized cancer treat-
ment, therefore, would be the application of multigene testing,
using a small amount of DNA, to generate a more compre-
hensive assessment ofmutations in several genes concurrently,
in a more clinically relevant time frame. Although several
challenges need to be overcome to implement such a para-
digm,14e18 such as generating high-quality genomic data from
archival [eg, formalin-ﬁxed, parafﬁn-embedded (FFPE)]
tumor material, this information can inform a precision or
individualized approach to clinical decision making, particu-
larly in selecting an appropriate targeted therapy for a patient.
Furthermore, the ability to combine multiple common target-
able alterations in one assay greatly enhances the ability to
identify patients who might be suitable candidates for clinical
trials of investigational therapies and to implement such testing
on all patients in the cancer center facilitates the imple-
mentation of basket trials that extend beyond speciﬁc
anatomically deﬁned cancer types.
To this end, in the past few years we have developed a
panel-based test that allows more broad screening of
genomic alterations known to be informative in cancer. We
and others have used mass spectrometric genotyping7 or
allele-speciﬁc PCR technologies19 to establish personalized
cancer medicine initiatives.7,19e25 More recently, advances
in next-generation sequencing technologies have enabled
even more comprehensive genomic characterization in a
massively parallel fashion and in a relatively short time
frame, allowing the assessment of many types of genomic
alterations (mutations, insertions and deletions, copyThe Journal of Molecular Diagnostics - jmd.amjpathol.orgnumber alterations, structural rearrangements, and epige-
netic changes) in hundreds or thousands of genes (targeted
sequencing and whole-exome sequencing), whole-genome
sequencing, transcriptome sequencing (RNASeq), and
epigenetic interrogations (methyl-Seq and ChipSeq). Pilot
studies that apply massively parallel sequencing technolo-
gies and/or integrative analyses in focused clinical settings
for a few patients have also been reported.26,27
We implemented a prospective genomic characterization
study called Proﬁle that aimed to apply genomic technolo-
gies to advance the ﬁeld of precision oncology by
addressing some of the challenges described above. We
obtained consent from >12,000 patients with cancer who
came to Dana-Farber Cancer Institute or Brigham and
Women’s Hospital between August 2011 and June 2013,
and OncoMap,7,28 a mass spectrometric genotyping assay
that detects 471 unique mutations in 41 cancer genes, was
performed in a laboratory certiﬁed by Clinical Laboratory
Improvement Amendments. Test results were reviewed by
laboratory staff and interpreted and reported by board-
certiﬁed pathologists. Here, we report initial ﬁndings from
proﬁles on >5000 patients with cancer.
Materials and Methods
Patients and Tumor Tissue Collection
Patients gave consent to the institutional review boarde
approved protocol 11 to 104 from the Dana-Farber Cancer
Institute Ofﬁce for the Protection of Research Subjects.
Tumor specimens were obtained from Dana-Farber Cancer
Institute and the Department of Pathology at Brigham and
Women’s Hospital. Patient charts were reviewed, and
appropriate specimens for testing were selected with the
following criteria: 30% viable tumor content (initially
50% tumor was required but this was decreased over time
because performance metrics were comparable) and sufﬁ-
cient area (>3 mm in greatest linear diameter) for DNA
extraction. Specimen types proﬁled included FFPE, fresh/
frozen, and blood/bone marrow.
DNA Extraction and Preparation
For solid tumor specimens, tissue was sectioned and slides
stained with hematoxylin and eosin were obtained. Tumor-rich
areas of FFPEweremanually dissected fromunstained slides or
whole FFPE blocks; fresh tissues were grossly minced and
digested overnight with Proteinase K. DNA was extracted
manually or by using an automated protocol (QiaSymphony)
withQiagen reagents (Qiagen,Valencia,CA).Blood ormarrow
samples with mononuclear hematological malignancies were
enriched by Ficoll gradient before DNA extraction. Total DNA
of 200 ngwas required to proceedwithOncoMap testing.DNA
(100 ng) extracted from FFPE samples was whole genome
ampliﬁed (GenomePlex Complete Whole Genome Ampliﬁca-
tion kit; Sigma-Aldrich, St. Louis,MO) for iPLEX analysis (see661
Table 1 Forty-One Genes and 471 Mutations Interrogated in OncoMap Version 4
Gene AA change Gene AA change Gene AA change Gene AA change Gene AA change
ABL1 M244V CSF1R Y969* FGFR2 N549K KRAS Q61R PIK3R1 N564K
ABL1 L248V CTNNB1 A13T FGFR3 R248C KRAS A146T PIK3R1 R574fs*27
ABL1 G250E CTNNB1 A21T FGFR3 S249C MAP2K1 Q56P PIK3R1 T576del
ABL1 Q252H CTNNB1 V22A FGFR3 G370C MAP2K1 K57N PIK3R1 W583del
ABL1 Q252H CTNNB1 V22_G38del FGFR3 S371C MAP2K1 K57N PTEN K6fs*4
ABL1 Y253F CTNNB1 W25_D32del FGFR3 Y373C MAP2K1 D67N PTEN R130G
ABL1 Y253H CTNNB1 D32A FGFR3 K650Q MAP2K1 C121S PTEN R130Q
ABL1 E255K CTNNB1 D32G FGFR3 G697C MAP2K1 C121S PTEN R130*
ABL1 E255V CTNNB1 D32H FGFR3 L794fs*23 MAP2K1 P124L PTEN R130fs*4
ABL1 D276G CTNNB1 D32N FLT3 Y572C MET T1010I PTEN R173C
ABL1 T315I CTNNB1 D32V FLT3 D835del MET H1112R PTEN R173H
ABL1 F317L CTNNB1 D32Y FLT3 D835E MET H1112Y PTEN R233*
ABL1 M351T CTNNB1 S33C FLT3 D835E MET Y1248C PTEN P248fs*5
ABL1 E355G CTNNB1 S33F FLT3 D835H MET Y1248H PTEN P248fs*5
ABL1 F359V CTNNB1 S33Y FLT3 D835V MET M1268T PTEN K267fs*9
ABL1 H396R CTNNB1 G34E FLT3 D835Y MLH1 V384D PTEN V317fs*3
AKT1 E17K CTNNB1 G34R FLT3 I836del MYC P57S PTEN N323fs*2
AKT2 S302G CTNNB1 G34R FLT3 I836M MYC A59V PTEN N323fs*21
AKT2 R371H CTNNB1 G34V GNA11 Q209L MYC T73I PTEN R335*
APC R876* CTNNB1 S37A GNA11 Q209P MYC S77F RB1 E137*
APC R1114* CTNNB1 S37C GNAQ Q209L MYC N101T RB1 L199*
APC E1306* CTNNB1 S37F GNAQ Q209L MYC P260A RB1 R320*
APC E1309fs*4 CTNNB1 S37P GNAQ Q209P NPM1 W288fs*12 RB1 R358*
APC E1309fs*6 CTNNB1 S37Y GNAS R201C NPM1 W288fs*12 RB1 R455*
APC Q1338* CTNNB1 T41A GNAS R201H NPM1 W288fs*12 RB1 R552*
APC Q1367* CTNNB1 T41I GNAS Q227L NRAS G12A RB1 R556*
APC Q1378* CTNNB1 T41P HRAS G12C NRAS G12C RB1 R579*
APC E1379* CTNNB1 T41S HRAS G12D NRAS G12D RB1 L660fs*2
APC Q1429* CTNNB1 T41S HRAS G12R NRAS G12R RB1 C706F
APC R1450* CTNNB1 S45A HRAS G12V NRAS G12S RB1 E748*
APC S1465fs*3 CTNNB1 S45C HRAS G13C NRAS G12V RET F612_C620del
APC T1556fs*3 CTNNB1 S45F HRAS G13R NRAS G13A RET D631G
BRAF R444W CTNNB1 S45P HRAS G13S NRAS G13C RET D631_L633>E
BRAF G464E CTNNB1 S45Y HRAS G13V NRAS G13D RET E632_L633del
BRAF G464R EGFR G719A HRAS Q61H NRAS G13R RET E632_L633>V
BRAF G464V EGFR G719C HRAS Q61H NRAS G13S RET E632_A640>VRP
BRAF G466A EGFR G719D HRAS Q61K NRAS G13V RET C634R
BRAF G466E EGFR G719S HRAS Q61L NRAS A18T RET C634W
BRAF G466R EGFR L730F HRAS Q61P NRAS Q61E RET C634Y
BRAF G466V EGFR W731* HRAS Q61R NRAS Q61H RET E768D
BRAF G469A EGFR P733L HRAS Q61R NRAS Q61H RET A883F
BRAF G469E EGFR E734K HRAS Q61R NRAS Q61K RET A883F
BRAF G469R EGFR G735S IDH1 R132C NRAS Q61L RET D898_E901del
BRAF G469R EGFR V742A IDH1 R132H NRAS Q61L RET M918T
BRAF G469S EGFR K745R IDH1 R132S NRAS Q61P SRC Q531*
BRAF G469S EGFR E746K IDH2 R140Q NRAS Q61R STK11 Q37*
BRAF G469V EGFR E746_A750del IDH2 R172K NRAS Q61R STK11 E57fs*7
BRAF V471F EGFR E746_A750del JAK2 V617F PDGFRA V561D STK11 Q170*
BRAF N581S EGFR E746_A750>V JAK3 P132T PDGFRA S566_E571>K STK11 D194N
BRAF E586K EGFR E746_T751del JAK3 A572V PDGFRA S566_E571>R STK11 D194V
BRAF D587A EGFR E746_T751>A JAK3 V722I PDGFRA S566_E571>R STK11 G196V
BRAF D587E EGFR E746_S752>A KIT D52N PDGFRA R841_D842del STK11 E199K
BRAF D587E EGFR E746_S752>V KIT Y503_F504insAY PDGFRA D842I STK11 E199*
BRAF I592M EGFR L747_R748>FP KIT K550_K558del PDGFRA D842V STK11 F264fs*22
BRAF I592V EGFR L747_E749del KIT W557G PDGFRA D842Y STK11 P281L
BRAF D594E EGFR L747_A750>P KIT W557R PDGFRA D842Y STK11 P281fs*6
BRAF D594G EGFR L747_A750>P KIT W557R PDGFRA D842_M844del STK11 W332*
(table continues)
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Table 1 (continued )
Gene AA change Gene AA change Gene AA change Gene AA change Gene AA change
BRAF D594V EGFR L747_T751del KIT K558_V560del PDGFRA D842_H845del TP53 R175H
BRAF F595L EGFR L747_T751>P KIT K558_E562del PDGFRA D842_H845>V TP53 G245S
BRAF F595S EGFR L747_T751>S KIT V559A PDGFRA D842_D846>E TP53 R248Q
BRAF G596R EGFR L747_S752del KIT V559D PDGFRA D842_D846>G TP53 R248W
BRAF L597Q EGFR L747_P753>Q KIT V559del PDGFRA D842_D846>N TP53 R273C
BRAF L597R EGFR L747_P753>S KIT V559G PDGFRA D842_S847>EA TP53 R273H
BRAF L597S EGFR A750P KIT V559I PDGFRA I843_D846del TP53 R306*
BRAF L597V EGFR S752Y KIT V560D PDGFRA I843_S847>T VHL P81S
BRAF T599I EGFR S752_I759del KIT V560G PDGFRA H845_N848>P VHL L85P
BRAF T599_V600insTT EGFR P753S KIT L576P PDGFRA D846Y VHL L89H
BRAF V600A EGFR D761N KIT P585P PIK3CA R88Q VHL F148fs*11
BRAF V600D EGFR D761Y KIT K642E PIK3CA N345K VHL L158Q
BRAF V600E EGFR S768I KIT V654A PIK3CA C420R VHL R161*
BRAF V600E EGFR V769_D770insASV KIT T670I PIK3CA P539R VHL R167W
BRAF V600K EGFR V769_D770insASV KIT D816H PIK3CA E542K
BRAF V600L EGFR D770_N771insN KIT D816V PIK3CA E542Q
BRAF V600L EGFR N771_P772>SVDNR KIT D816Y PIK3CA E545A
BRAF V600M EGFR P772_H773insV KIT N822K PIK3CA E545D
BRAF V600R EGFR H773R KIT N822K PIK3CA E545D
BRAF K601del EGFR I744_A750>VK KIT V825A PIK3CA E545G
BRAF K601E EGFR T790M KIT E839K PIK3CA E545K
BRAF K601N EGFR G810D KRAS G12A PIK3CA E545Q
BRAF K601N EGFR G810S KRAS G12C PIK3CA Q546K
BRAF S605F EGFR L858M KRAS G12D PIK3CA H701P
BRAF S605N EGFR L858R KRAS G12R PIK3CA Y1021C
CDK4 R24H EGFR L858R KRAS G12S PIK3CA M1043I
CDKN2A R58* EGFR L858R KRAS G12V PIK3CA M1043I
CDKN2A E61* EGFR L861Q KRAS G13A PIK3CA H1047L
CDKN2A E69* ERBB2 L755P KRAS G13C PIK3CA H1047R
CDKN2A R80* ERBB2 L755S KRAS G13D PIK3CA H1047Y
CDKN2A H83Y ERBB2 D769H KRAS G13R PIK3CA G1049R
CDKN2A D84Y ERBB2 Y772_A775dup KRAS G13S PIK3CA G1049S
CDKN2A E88* ERBB2 A775_G776insYVMA KRAS G13V PIK3CA N1068fs*4
CDKN2A D108Y ERBB2 G776S KRAS L19F PIK3R1 G376R
CDKN2A W110* ERBB2 G776VC KRAS L19F PIK3R1 G376R
CDKN2A W110* ERBB2 V777L KRAS Q22K PIK3R1 E439del
CDKN2A P114L FGFR1 S125L KRAS A59T PIK3R1 K459_S460>N
CSF1R L301S FGFR1 P252T KRAS Q61E PIK3R1 R461*
CSF1R L301* FGFR2 S252W KRAS Q61H PIK3R1 R557_K561>Q
CSF1R Y969C FGFR2 K310R KRAS Q61H PIK3R1 D560Y
CSF1R Y969F FGFR2 S372C KRAS Q61K PIK3R1 D560_S565del
CSF1R Y969H FGFR2 Y375C KRAS Q61L PIK3R1 N564D
CSF1R Y969* FGFR2 C382R KRAS Q61P PIK3R1 N564K
Enterprise-Wide Cancer Sequencingimmediately below), whereas fresh frozen and blood DNAwas
processed with unampliﬁed DNA. Conﬁrmation of mutations
was performed on unampliﬁed genomic DNA by using ho-
mogenous mass-extend chemistry.29
OncoMap Assay Design and Genotyping
Selection of cancer gene mutations for assay design and mass
spectrometric genotyping was performed as previously
described.7 Specimens were genotyped with OncoMap
version 4, which assays 471 unique mutations in 41 cancer-
related genes (Table 1). OncoMap version 4 identiﬁes mu-
tations in a high-throughput manner such that 48 to 96 patientThe Journal of Molecular Diagnostics - jmd.amjpathol.orgsamples are processed in parallel and consists of two chem-
istries (high complexity iPLEX5 and homogenous mass-
extend) and a manual review step, as previously described.7
Genomic proﬁling was performed in an environment certi-
ﬁed by Clinical Laboratory Improvement Amendments.
OncoMap Validation
Validation studies were performed to determine precision, ac-
curacy, sensitivity, speciﬁcity, and limit of detection by using
blood, fresh frozen, and FFPE samples that had existing
genomic characterization by using an orthogonal clinical test
(eg, pyrosequencing, Sanger sequencing, PCR/electrophoresis,663
Table 2 Distribution of Cancer Types Assayed in Our Cohort of
Patient Samples, Consisting of 24 Major Cancer Types








Female genital tract 157
Genitourinary tract 218
Head and neck carcinoma 149
Kidney carcinoma 153
Liver carcinoma 29











Upper GI tract 168
Total 5118
GI, gastrointestinal.
MacConaill et alreal-timePCR).Thirty sampleswith knownmutations inKRAS,
EGFR, BRAF, TP53, AKT, and PIK3CA were selected. Within
this sample set, additional mutations identiﬁed in APC, P53,
CTNNB1, and JAK3 were also assessed for a total of 28 ge-
netic variants detectable by 53 individual assays. Normal
(noncancerous) liver was included to verify detection of
wild-type loci. To obtain sufﬁcient quantities of DNA,
several isolations were performed from each FFPE sample,
pooled to ensure sample homogeneity, and then divided into
aliquots to produce nine replicates. OncoMapwas performed
in triplicate across three experiments to determine intra- and
inter-run precision.
A total of 114 samples (41 wild-type and 73 mutant) were
analyzed by reference methods (pyrosequencing, PCR/CE
fragment analysis, Sanger sequencing, and allele-speciﬁc
PCR) at the Center for Advanced Molecular Diagnostics,
Brigham and Women’s Hospital, and were subsequently
analyzed in OncoMap to determine accuracy and concor-
dance with gold standard methods for variants at the
following loci: KRAS G12 and G13; NRAS G12, G13, and
Q61; EGFR exon 19 (deletion); JAK2 V617F; EGFR
L858R; and KIT exon 11 (deletion).
To assess our ability to detect all 471 mutations in 439
assays, we designed synthetic oligonucleotides that harbored
each of the genetic variants listed in Table 1 (IDT, Coralville,
IA). These were pooled into groups of three nonoverlapping
variants and spiked into normal liver DNA isolated from
FFPE tissue such that the ratio of wild-type to variant was 1:1
and were analyzed with OncoMap. The limit of detection was
determined by mixing genomic DNAs isolated from the
following cell lines: THP-1 (NRASG12D; ATCC, Rockville,
MD), PC9-2 (EGFR E746-A750del), H1975 (EGFR L858R
and T790M), and A-549-2 (KRAS G12S; gift from Dr. Pasi
Janne, Dana-Farber Cancer Institute). Six replicates were
prepared at deﬁned ratios representing 0%, 5%, 7.5%, 10%,
and 25% allele frequencies for ﬁve known variants and
assessed in OncoMap. Ninety-ﬁve percent conﬁdence in-
tervals were calculated with R version 2.15.0 (R Project for
Statistical Computing, Vienna, Austria; http://www.r-
project.org) by using the binconf function in the Hmisc
package. The calculation method used the Wilson score in-
terval to generate the conﬁdence interval.
Results
Characteristics of Clinical Tumor Cohort
Of 9950 patients with an available specimen accessioned in
the pathology laboratory, 5372 (53.9%) were estimated by a
pathologist to have sufﬁcient and appropriate material to
attempt DNA extraction. Of these, 5123 patients had sufﬁ-
cient DNA (200 ng or more) to proceed with OncoMap, and
99.9% (n Z 5118) of attempted tests yielded an OncoMap
result. Estimated tumor content exceeded 30% in all speci-
mens as determined by pathological review (hematoxylin
and eosin evaluation).664The distribution of cancer types assayed in our cohort is
depicted in Table 2, and consists of 24 main cancer types. This
distribution of cases reﬂected the population of cancers for
which the test was ordered and performed and was not
necessarily reﬂective of the incidence of cancer types seen at
our institutions; the distribution of cases was likely skewed by
both differences in the availability of appropriate materials/
specimens for testing and differences in ordering habits of the
involved physicians. Specimens (n Z 5118) yielded an
OncoMap result. Of these, 451 specimens were obtained from
frozen tissue, 74 from blood, 189 from bonemarrow, and 4404
(86%) from FFPE blocks. Specimens (n Z 2182; 42.6%)
harbored one or more mutations. Specimens with mutations
(74.4%) had one mutation identiﬁed by OncoMap, approxi-
mately one-third of reportable cases. Twenty percent of
specimens with mutations (8.5% of reportable cases) had two
mutations; the remainder had between three and ﬁve events.
All specimens with four or more mutations (n Z 22) were
identiﬁed as either colorectal or endometrial adenocarcinoma.
Performance of OncoMap
To facilitate cancer gene mutation proﬁling in clinical tumor
specimens, we used OncoMap version 4, a panel of geno-
typing assays that assessed the status of 471 mutations,
across 41 cancer-related genes. The complete mutation
proﬁling algorithm, including iPLEX chemistry, automatedjmd.amjpathol.org - The Journal of Molecular Diagnostics
Enterprise-Wide Cancer Sequencingcalling, manual review, validation by using homogenous
mass-extend chemistry, and manual review by laboratory
personnel and a pathologist, has been previously reported7;
a schematic overview of the process, including the time
taken for each step, is indicated in Figure 1.
Validation studies have found 100% intra- and inter-
assay precision (95% CI, 99.2%e100%), because all 28
genetic variants (seeMaterials and Methods) were detected
in nine of nine replicates in the expected 53 assays.
Concordance studies that compared OncoMap with various
validated methods for single gene testing reported 98.3%
sensitivity (95% CI, 94.13%e99.54%) and 100% speci-
ﬁcity (95% CI, 98.1%e100%) for KRAS, NRAS, BRAF,
JAK2, KIT, and EGFR. Two samples gave a false negative
OncoMap result for JAK2 V617F, both with allele fre-
quency <1%. Further evaluation of all 471 genetic variants
that used synthetic oligonucleotides found the expected
mutation in 432 of 439 assays; 7 assays displayed poor
performance and failed to detect the expected mutation. For
each of the seven failing assays, at least one additional
complementary assay (ie, the opposite strand) detected the
variant in question, with no false positives, resulting in an
overall sensitivity and speciﬁcity of 100% (95% CI,
99.19%e100%). Limit of detection experiments performed
on cell lines with known genetic variants mixed in deﬁned
ratios to produce allele frequencies that varied between 0%
and 25% found successful detection (100%; 95% CI,
88.65%e100%) to 7.5%mutant allele frequency for each of
the ﬁve mutations monitored (EGFR T790M, EGFR
L858R, EGFR E746-A750del, NRAS G12D, and KRASFigure 1 Technical and bioinformatics steps in the clinical diagnostics pipelin
weeks. hMe, homogenous mass-extend; QC, quality control.
The Journal of Molecular Diagnostics - jmd.amjpathol.orgG12S); EGFR T790M and EGFR L858R were also detected
(100%; 95% CI, 75.75%e100%) at 5% allele frequency.
Expected Mutations in Well-Characterized Cancer Types
In total, 2890 mutations were identiﬁed in our cohort. The
spectrum of mutations by gene is shown in Figure 2. As ex-
pected, KRAS was the most commonly mutated gene in our
cancer population, occurring in 538 samples (10% of all sam-
ples) or almost 20% of mutated samples. The next most
commonly mutated gene was PIK3CA (497 instances; 17% of
mutations), followed by TP53 (326 instances; 11%) and BRAF
(202 instances corresponding to 7% of mutations). The TP53
mutation frequencywas less thanmight be expected but may be
explained by the ability of a genotyping technology to detect
only speciﬁc, predetermined mutations incorporated into the
assay design. This was a limitation when interrogating tumor
suppressor genes such as TP53, which may have many loss-of-
function mutations scattered throughout the gene (eg, this plat-
form can detect only approximately 20% of the known TP53
mutations, by frequency, in the Catalogue of SomaticMutations
inCancer30 database). The full landscape ofmutations by cancer
type is indicated in Figure 3. CDK4, CSF1R, FGFR1, and SRC
were not detectably mutated in any of the cases.
Interpretation of Mutations
A tiering approach was designed to assess the import of
genomic alterations in speciﬁc cancer types. Each mutation
was assigned one of three tiers. In tier 1, the alteration hase. The timeline from receipt of specimen to generation of a report is 3 to 4
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Figure 2 Incidence of mutations by gene in our cancer cohort. Of the 2890
mutations detected in 5118 patients, approximately 19% were KRASmutations,
followed by PIK3CA (17% of mutations), TP53 (11%), and BRAF (7%).
MacConaill et alwell-established published evidence to conﬁrm clinical utility
in this tumor type, in at least one of the following contexts:
predicting response to treatment with a therapy approved by
the Food and Drug Administration, assessing prognosis,
establishing a deﬁnitive diagnosis, or conferring an inherited
increased risk of cancer to this patient and family. In tier 2,
the alteration may have clinical utility in at least one of the
following contexts: selection of an investigational therapy in
clinical trials for this cancer type; limited evidence of prog-
nostic association; supportive of a speciﬁc diagnosis; proven
association of response to treatment with a therapy approved
by the Food and Drug Administration in a different type of
cancer; or similar to a different mutation with a proven as-
sociation with response to treatment with a therapy approved
by the Food and Drug Administration in this type of cancer.
In tier 3, the alteration is of uncertain clinical utility but may
have a role as suggested by at least one of the following:
demonstration of association with response to treatment in
this cancer type in preclinical studies (eg, in vitro studies or
animal models); alteration in a biochemical pathway that has
other known, therapeutically targetable alterations; alteration
in a highly conserved region of the protein predicted, in666silico, to alter protein function; or selection of an investiga-
tional therapy for a different cancer type. Of all specimens
tested, 26% have at least one tier 1 (10%) or tier 2 (16%)
mutation, which may directly affect clinical decision making.
As previously described, we identiﬁed known driver mu-
tations in well-characterized cancers, KRAS mutations in
colorectal cancer, endometrial cancer, and lung cancer; BRAF
mutations in melanoma, papillary thyroid carcinoma, and
colorectal adenocarcinoma; PIK3CA mutations in breast,
lung, and endometrial cancers; EGFR and KRAS mutations in
lung adenocarcinoma; and IDH1 mutations in gliomas. As
expected, the distribution of mutations reﬂected patterns
previously observed in human tumors, although the fre-
quency of tumor suppressor mutations was lower (reﬂective
of the reduced coverage of such mutations by OncoMap).
Mutations Predicting Response/Resistance to Targeted
Therapies
Receptor Tyrosine Kinases EGFR, ERBB2, KIT, PDGFRA
Our genotyping test robustly detected mutations that constitute
established markers of response to targeted therapies. EGFR
mutations predictive of response to erlotinib and geﬁtinib were
identiﬁed at 8.6% frequency in non-small cell lung cancer,
which is a little lower than expected. This is because of the
inability of a genotyping approach to detect eachof thepossible,
variable, EGFR exon 19 deletions. Of note, we identiﬁed
two lung adenocarcinomas with co-occurring EGFR L858R
and T790M mutations. L858R indicated sensitivity to a TKI
therapy, and the presence of a T790M (usually) indicated that
resistance to a TKI has emerged. In one case, the specimen
tested was a post-TKI relapse specimen, with the L858R allele
present at approximately 40% to 50% as determined by relative
peak heights of Sequenom assays, and the T790M mutation
present in approximately 2% of alleles. Interestingly, in the
second case, the patient had a history of multifocal lung
adenocarcinoma, and two specimens tested (one from2008, one
from 2012) were genomically distinct; the more recent tumor
contained a baseline de novoT790M, which, although rare, hasFigure 3 Landscape of mutations by gene in
our cancer cohort. The frequency of gene mutation
(normalized by the number of samples in each
category) is indicated on the y axis, genes mutated
on the x axis, and cancer type on the z axis. GI,
gastrointestinal.
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response to EGFR TKIs.31 In this case, the allele fraction (as
determined by peak height) of the L858R allele was also higher
(10% to 15%) than the T790M allele (approximately 5%).
Activating ERBB2 mutations were seen in 18 cases, 5
cases of lung adenocarcinomas, 4 cases of bladder cancer, 4
cases of female genital tract cancer, 3 cases of breast cancer,
1 case of colon cancer, and 1 case of kidney cancer. Inter-
estingly, in three cases ERBB2 mutations co-occurred with
canonical PIK3CA mutations, and in another two instances
(one colon, one ovarian) an ERBB2 mutation co-occurred
with a KRAS G12 or G13 mutation.
Fifty-six samples harbored canonical KIT or PDGFRA
mutations. Although 79%of thesewere gastrointestinal stromal
tumors, and an additional 3.5% were noncutaneous mela-
nomas, we also observed targetable mutations in mastocytosis
(n Z 3), germ cell tumors (n Z 3), a glioblastoma, an acute
leukemia, a thymus carcinoma, and an ovarian dysgerminoma.
Mutation proﬁling also identiﬁed mutations that confer
secondary resistance to targeted therapies (eg, resistance alleles
arising during the course of targeted therapy). Six instances of
PDGFRA mutation D842V or D842Y were identiﬁed in ﬁve
gastrointestinal stromal tumors and one glioblastoma, and these
alterations are predictive of resistance to imatinib in gastroin-
testinal stromal tumors32; recent in vitro data indicates potential
response to newer inhibitors of platelet-derived growth factor
receptor, a polypeptide (PDGFRA) such as crenolanib.33
RAS/RAF/MEK/ERK Pathway
BRAF V600E mutations linked to sensitivity to inhibitors such
as vemurafenib were detected in 44% of papillary thyroid can-
cers and 34% of melanomas. In addition, activating BRAF
mutations were also detected in rarer cancers or at lower fre-
quencies such as Langerhans cell histiocytosis,34 hairy cell
leukemia,35 metanephric adenoma36; pancreatic breast, ovarian,
and prostate adenocarcinoma,37 indicating the utility of
exploring a targeted inhibitor38 for these speciﬁc patients.
Interestingly, we observed two cases of lung adenocarcinoma
and one urinary bladder cancer with co-occurring BRAF and
KRAS mutations; in each case the BRAF alterations were non-
V600E mutations (G464E, G466E, L597V). One instance in a
colorectal adenocarcinoma exhibitedBRAFV600E and aKRAS
G12D mutation. With mutations that confer heightened sensi-
tivity to targeted therapies, OncoMap robustly detected muta-
tions associated with resistance to several agents. Established
examples include KRAS mutations in lung cancer (23%), colo-
rectal cancer (42%), and endometrial cancer (20%) that confer
resistance to erlotinib, geﬁtinib (lung cancer), or cetuximab
(colorectal cancer).39e41HRASmutationswere identiﬁed in 2 of
10 adrenal gland pheochromocytomas, as recently reported.42
Similarly, we identiﬁed MEK1 (MAP2K1) mutations in
11 specimens, four lung adenocarcinomas, one oral squa-
mous cell carcinoma, three gastrointestinal tract adenocar-
cinomas, a breast cancer, a thymoma, and a hairy cell
leukemia. MEK1 mutations have previously been identiﬁed
in malignant melanomas43 whereby they often occur withThe Journal of Molecular Diagnostics - jmd.amjpathol.orgBRAF or NRAS mutations; there is evidence that some
MEK1 mutations may confer resistance to MEK [mitogen
activated protein (MAP) extracellular signal-related kinase
(ERK) kinase]/RAF inhibitors in melanoma.
PI3K/AKT/Mammalian Target of Rapamycin Pathway
Inhibitors of the PI3K/AKT/mammalian target of rapamycin
pathway have found promise in preclinical and clinical trials in
multiple cancer types.44 We identiﬁed gain-of-function AKT1
E17K mutations in several meningiomas (as recently identiﬁed
by our group with the use of whole-genome and whole-exome
sequencing45), an oral squamous cell carcinoma, a liposarcoma,
and the more common events in breast, colorectal, ovarian,46
endometrial,7 and lung6 adenocarcinomas. This mutation may
predict resistance to PI3K inhibition (and conceivably receptor
tyrosine kinase inhibition) in some contexts.46 Three hundred
sixty-nine additional samples (7% of all patients tested) across
all cancer types (predominantly breast) harbored mutations in
PIK3CA, PIK3R1, PTEN, or a combination thereof. These
mutations might be expected to enrich for tumors responsive to
the PI3K inhibitors currently in development.
Metabolic and Other Signaling Pathways
Several tumors harbored mutations that may have prog-
nostic and therapeutic relevance. For example, IDH1 and
IDH2 gain-of-function mutations have been identiﬁed in
leukemias47 and glioblastomas48; in our cohort we identiﬁed
IDH1 mutations in these cancers, less commonly in mela-
noma49 (n Z 4), chondrosarcoma,50 cholangiocarcinoma,51
and prostate cancer52 but also in previously unreported
cancers such as lung, colorectal, and endometrial adeno-
carcinomas and a urinary bladder carcinoma.
We identiﬁed 28 samples with GNAS mutations across
many cancer types, some known (lung, pancreatic, and
colorectal adenocarcinoma) but also in breast, ovarian, and
cervical cancers. All but one of the GNAS mutations were
codon 201 in exon 8; there was one instance of codon 227
mutation in exon 9. Clinically, GNAS mutations in pituitary
neoplasms have been associated with increased sensitivity to
octreotide (somatostatin agonist) in some studies.53
Noncanonical Mutations in Potentially Actionable
Genes
Although genotyping assumes an a priori knowledge of
speciﬁc regions in a gene that may be mutated, the mass
spectrometric genotyping assay described here can be
designed to incorporate additional sites in genes that may be
known to be mutated at a lesser frequency. Although not as
comprehensive as full-length sequencing of a gene, Onco-
Map nonetheless provides more information for some genes
than current gold standard clinical tests such as pyrose-
quencing. For example, somatic mutations of BRAF occur at
high frequency in numerous human cancers,54 and the
BRAF V600E mutation (resulting in increased kinase ac-
tivity) accounts for >90% of described mutations;667
MacConaill et alpyrosequencing is often used to detect mutations in amino
acids 599 to 601 only. In our cohort, of 202 BRAFmutations
identiﬁed, 34 (17%) were non-V600 mutations, and 8 were
indels at/near the V600 locus that were not the canonical
c.1799T>A nucleotide change. Although we do not yet
know the full implication of all these alterations, we know
that V600E- or V600K-mutant tumors may indicate better
response to targeted therapies than patients with wild-type
tumors,55 and BRAF L597 mutations (seen in a colorectal
adenocarcinoma and a bladder carcinoma in our cohort)
may indicate sensitivity to MEK inhibitors in melanoma,56
indicating the utility of using a more comprehensive assay
when performing molecular proﬁles of patients’ tumors.
In addition, BRAF N581S in a bone marrow myelopro-
liferative neoplasm was identiﬁed; this mutation has been
seen rarely in several solid tumors,14,16,57 but to our
knowledge this is the ﬁrst BRAF mutation in myeloprolif-
erative neoplasm.
Missense Mutations in MET and JAK3 May Be Somatic
or Germline
MET T1010I (also known as T992I) mutations were observed
in a reasonable frequency of our cohort (2.55% of cases).
There is conﬂicting evidence in the literature about the trans-
forming ability of this alteration58,59; it has also been identiﬁed
as a heterozygous single nucleotide polymorphism in a normal
(noncancer) population at a frequency of 2.49% (European
American population; Exome Variant Server; National Heart,
Lung, and Blood Institute Grand Opportunity Exome
Sequencing Project, Seattle, WA; http://evs.gs.washington.
edu/EVS, last accessed November 2013; P Z 0.999, c2 test,
no signiﬁcant difference). Because our OncoMap tests were
performed on tumor specimens and not matched germline
samples, we cannot determine whether these represent somatic
or germline events or a mix of both. [However, the allele
frequencies (based on peak heights as the expected locations)
for the T1010I allele (expected 50% if heterozygous single
nucleotide polymorphism in diploid genome) ranged from
23% to 99% (mean, 46.5%; median, 46.4%), further sup-
porting the likelihood this is a germline variant.] Similarly,
evidence exists for the transforming ability of JAK3 alleles
P132T and V722I,60 but both are also found in normal pop-
ulations. The frequency of JAK3V722I alterations is 2.67% in
our cohort, compared with 2.56% in the Exome Sequencing
Project database (P Z 0.985), and JAK3 P132T occurs at a
frequency of 23 of 5118 cases (0.45%), compared with an
Exome Sequencing Project frequency of 0.05% (PZ 0.0043).
The difference in JAK3 P132T incidence in our cancer cohort
and a normal cohort may be due to differences in ancestral
populations (we used European American numbers as repre-
sentative of our cohort) or might indicate that (in some cases)
the single nucleotide polymorphisms might represent cancer
susceptibility single nucleotide polymorphisms; thorough
analysis of normal (noncancer) specimen would be necessary
to support this.668Cancers with Co-Occurring Actionable Mutations
The presence of co-occurringmutations in known cancer genes
may modify the clinical response to single-agent targeted
therapy. In our cohort, 435 patient samples had two mutations,
101 had three mutations, and 22 had four or more mutations
(Table 3). Of the 536 cases with two or three mutations,
PIK3CA was the most frequently co-occurring mutated gene,
with 204 specimens harboring mutant PIK3CA with another
gene (most often TP53). Twelve specimens had two mutations
within PIK3CA. Samples (nZ 206) had a KRASmutation and
another mutation; 134 samples had a TP53 mutation with
another mutation; and 61 specimens (mostly endometrial,
breast, lung, and ovarian adenocarcinomas) harbored KRAS
and PIK3CA mutations. As we previously noted, coincident
mutations in these genes have been reported in cancers of the
large intestine,61 but they have typically exhibited a mutually
exclusive pattern of occurrence in endometrial cancer.55 Fifty-
nine cases had KRAS and APC mutations.
Discussion
One of the goals of precision cancer medicine is to combine
genetic, genomic, and molecular characterization of a tumor
with contextual information on anatomical site and other
histological criteria to generate a more accurate diagnosis,
prognosis, and/or choice of therapy for a patient. In contrast
to many existing clinical tests that focus on one or a small
number of gene alterations, newer technologies allow the
simultaneous interrogation of many cancer genes. We pre-
viously reported the adaptation of genotyping-based muta-
tion proﬁling for the characterization of both frozen and
FFPE-derived tumor specimens in a research setting.7 The
intent of the Proﬁle study was to initiate an enterprise-level
genomic characterization study wherein the logistical and
scientiﬁc barriers to implementation of a precision cancer
medicine approach could be identiﬁed and resolved.
Although Proﬁle testing generates clinical-grade results in a
laboratory certiﬁed by Clinical Laboratory Improvement
Amendments, most genotyping results from such a broad
panel have no known clinical meaning for most patients with
cancer. Therefore, we initially considered this to be a research
test and developed a consenting process for patients.
Of patients who consented, approximately 25% had a
specimen at an outside hospital that was not available for
testing. Of the 9950 that had consent and material available
in our department for testing, >50% were estimated by a
pathologist to have sufﬁcient material to test, and, of these,
approximately 95% yielded an OncoMap result.
The success rate of generating a proﬁle for a patient who
gave consent can be enhanced by improving access to
material at other institutions/pathology departments and by
using a platform that requires less input DNA (eg, our
experience with next-generation sequencing technologies is
that they require less than half the amount of input DNA
needed for OncoMap).jmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 3 Samples with Co-Occurring Mutations in Our Cancer Cohort
Combination Count Combination Count Combination Count Combination Count
ABL1-ABL1* 1 CDKN2A-HRAS 1 FLT3-NPM1 2 KRAS-PIK3CA 34
AKT1-BRAF 1 CDKN2A-IDH1 1 GNAS-KRAS 9 KRAS-PIK3CA-PIK3CA 1
AKT1-CTNNB1 3 CDKN2A-IDH1-NRAS 1 GNAS-KRAS-PIK3CA 1 KRAS-PIK3CA-PTEN 5
AKT1-CTNNB1-PTEN 1 CDKN2A-JAK3 2 GNAS-KRAS-TP53 3 KRAS-PIK3CA-TP53 4
AKT1-JAK3 3 CDKN2A-KRAS 2 GNAS-MET 1 KRAS-PIK3R1 1
AKT1-JAK3-TP53 1 CDKN2A-KRAS-MET 1 GNAS-TP53 1 KRAS-PIK3R1-PTEN 1
AKT1-KRAS 3 CDKN2A-KRAS-TP53 1 HRAS-JAK3 2 KRAS-PTEN 8
AKT1-KRAS-PTEN 2 CDKN2A-NRAS 1 HRAS-MET 1 KRAS-STK11 3
AKT1-NRAS-PIK3CA 1 CDKN2A-PIK3CA 1 HRAS-PIK3CA 5 KRAS-TP53 27
AKT1-PIK3CA 1 CDKN2A-PIK3CA-TP53 1 IDH1-JAK3 4 MAP2K1-PIK3CA 1
AKT1-TP53 2 CDKN2A-TP53 3 IDH1-KRAS 1 MET-NRAS 2
APC-APC* 1 CTNNB1-EGFR 3 IDH1-MET 1 MET-PIK3CA 7
APC-APC-KRAS 6 CTNNB1-EGFR-EGFR 1 IDH1-NPM1 1 MET-PIK3CA-PTEN 1
APC-BRAF 1 CTNNB1-EGFR-JAK3 1 IDH1-NRAS 2 MET-PIK3CA-TP53 1
APC-BRAF-TP53 1 CTNNB1-FGFR2-PTEN 1 IDH1-PIK3CA-PTEN 1 MET-RB1 1
APC-CDKN2A-KRAS 1 CTNNB1-FGFR3 1 IDH1-PIK3R1 2 MET-TP53 9
APC-GNAS-KRAS 1 CTNNB1-GNAS-KRAS 1 IDH1-TP53 14 MYC-PTEN 1
APC-JAK3-KRAS 1 CTNNB1-JAK3-KRAS 1 IDH2-JAK3-MET 1 NPM1-NPM1* 1
APC-KRAS 24 CTNNB1-KRAS 10 IDH2-KIT 1 NPM1-NRAS 3
APC-KRAS-MET 1 CTNNB1-KRAS-PIK3CA 1 IDH2-NPM1 3 NRAS-NRAS* 1
APC-KRAS-PIK3CA 11 CTNNB1-KRAS-PTEN 2 IDH2-NPM1-NRAS 2 NRAS-PIK3CA 1
APC-KRAS-PTEN 1 CTNNB1-MET 1 IDH2-NRAS 2 NRAS-TP53 1
APC-KRAS-TP53 7 CTNNB1-PIK3CA 23 JAK2-KIT 1 PDGFRA-TP53 1
APC-MET 1 CTNNB1-PIK3CA-PIK3CA 1 JAK3-KRAS 5 PIK3CA-CTNNB1 1
APC-NRAS 2 CTNNB1-PIK3CA-PTEN 3 JAK3-KRAS-PIK3CA 2 PIK3CA-HRAS 1
APC-PIK3CA 3 CTNNB1-PIK3CA-TP53 1 JAK3-KRAS-PTEN 2 PIK3CA-KRAS 1
APC-PIK3CA-PTEN 1 CTNNB1-PIK3R1 4 JAK3-MAP2K1 1 PIK3CA-PIK3CA* 9
APC-PTEN 4 CTNNB1-PTEN 5 JAK3-MET 4 PIK3CA-PIK3R1 1
APC-RB1 1 CTNNB1-TP53 2 JAK3-NRAS 3 PIK3CA-PIK3R1-PTEN 1
APC-TP53 6 EGFR-EGFR* 2 JAK3-PIK3CA 12 PIK3CA-PTEN 10
BRAF-CDKN2A 2 EGFR-MLH1-PIK3CA 1 JAK3-PIK3CA-PIK3CA 1 PIK3CA-PTEN-PTEN 1
BRAF-GNAS 1 EGFR-PIK3CA 1 JAK3-PIK3R1 2 PIK3CA-RB1-TP53 1
BRAF-GNAS-PIK3CA 1 EGFR-TP53 2 JAK3-PTEN 2 PIK3CA-RET 1
BRAF-HRAS 1 ERBB2-KRAS 2 JAK3-TP53 6 PIK3CA-TP53 19
BRAF-IDH1 2 ERBB2-PIK3CA 3 KIT-KIT* 3 PIK3CA-TP53-TP53 1
BRAF-JAK3 3 FGFR2-KRAS-PIK3CA 1 KIT-KIT-PIK3CA 1 PIK3R1-PTEN 2
BRAF-JAK3-MET 1 FGFR2-PIK3CA 7 KIT-KRAS 1 PIK3R1-PTEN-PTEN 1
BRAF-JAK3-PIK3CA 1 FGFR2-PIK3CA-PTEN 1 KIT-PIK3CA-TP53 1 PTEN-PTEN* 2
BRAF-KRAS 4 FGFR2-PIK3CA-TP53 1 KIT-TP53 1 PTEN-PTEN-TP53 1
BRAF-MET 2 FGFR2-PTEN 3 KRAS-KRAS* 2 PTEN-RB1 1
BRAF-NRAS 1 FGFR2-TP53 1 KRAS-MET 6 PTEN-RB1-EGFR 2
BRAF-PIK3CA 8 FGFR3-KRAS 1 KRAS-MET-STK11 1 PTEN-TP53 2
BRAF-PIK3CA-STK11 1 FGFR3-PIK3CA 4 KRAS-MYC-PTEN 1 RB1-TP53 3
BRAF-PTEN 1 FGFR3-PTEN 1 KRAS-NPM1-NRAS 1 TP53-CTNNB1 1
BRAF-TP53 6 FGFR3-TP53-TP53 1 KRAS-NRAS 2 TP53-TP53* 1
More than 10% of specimens had two or three mutations. Combinations of gene mutations are indicated by underline.
*Co-occurring mutation within the same gene.
Enterprise-Wide Cancer SequencingA key performance characteristic is robust performance in
samples derived from FFPE and/or archival tumor material,
using a relatively small amount of DNA. Of patients with
sufﬁcient material to test, approximately 95% yielded an
OncoMap result. Of all samples tested, <0.1% failed geno-
typing, indicating the utility of a robust platform to screen for
cancer-driving mutations. Moreover, a variety of specimen
types (solid, blood, bone marrow), ﬁxation method (frozen,
fresh, FFPE), specimen age (0 to 10 years), and qualityThe Journal of Molecular Diagnostics - jmd.amjpathol.orgperformed well with this platform. OncoMap achieved 98.3%
overall sensitivity (95% CI, 94.13%e99.54%) and 100%
speciﬁcity (95% CI, 98.1%e100%), using clinically validated
reference tests as a benchmark, in both fresh/frozen and FFPE-
derived tumor DNA, indicating that false positive mutation
calls are likely to be relatively rare. The sensitivity of Onco-
Map, here determined as 5% to 10%, is less than real-time
PCR, comparable with pyrosequencing, and exceeds Sanger
sequencing, all of which are common cancer molecular669
MacConaill et aldiagnostic technologies. As previously noted,7 however,
achieving this level of speciﬁcity requires the implementation
of an analytical algorithm in which genotyping data are sub-
jected to automated and manual review of candidate mutations
and validation of all candidates by using alternative genotyp-
ing chemistries. Thus, clinical implementation of this partic-
ular platform requires both genomic data generation and
bioinformatic analysis in a molecular pathology or clinical
diagnostic setting. The resultant 3- to 4-week turnaround time
from specimen receipt to report generation (Figure 1), how-
ever, is less than ideal for some clinical cases.
Advances in our understanding of biological driver events
for some cancers, coupled with improvements in technolo-
gies used to detect somatic cancer alterations, have led to the
establishment of personalized cancer medicine programs at
several cancer centers in the United States.19e25,27,41,52
Most of these programs use some form of genotyping to
proﬁle patient samples for alterations in a panel of poten-
tially actionable or drugable gene mutations that may inform
a therapeutic paradigm for patients.
In this study, we report the clinical implementation of an
updated panel of assays interrogating 471 unique sites in 41
known cancer genes. More than 5000 OncoMap proﬁles were
generated over 2 years, from patients with cancer who gave
consent, spanning all cancer types across both solid tumors
and hematological malignancies.With the use of this panel, we
robustly detected mutations in more than one-third of patients
tested. Many of these mutations (26%) directly affect clinical
use (tier 1 and 2 alterations) and/or predict resistance to
existing agents such as TKIs (eg, EGFR and KRASmutations)
or investigational therapies currently in clinical trials. We also
identiﬁed multiple gene mutations that may guide the use of
emerging agents in speciﬁc cancer types, and we found the
value of applying this OncoMap platform across a large cohort
of patients with cancer. Some recent ﬁndings in rarer cancers
(such as meningiomas) that were originally identiﬁed by large-
scale whole-genome or whole-exome sequencing approaches
were recapitulated by using genotyping, resulting in the
description of mutations that may inform molecular classiﬁ-
cation and new therapeutic avenues. Finally, we determined
that in approximately 10% of cases examined tumor speci-
mens harbor expected and unexpected combinations of gene
mutations, thus reinforcing that a broad proﬁle of cancer-
driving mutations is informative and may help to further
elucidate differential patient responses to targeted therapies or
why a long tail of clinical response is seen in patient pop-
ulations selected for response to a particular therapy.
Although this study indicates the clinical utility of a high-
throughput, cost-effective approach to simultaneously detect
mutations in multiple cancer genes, we acknowledge the
technical limitations of genotyping, which restricts both the
number of genes and fraction of base pairs interrogated, the
type of alteration investigated (mostly single nucleotide sub-
stitutions and small insertions/deletions), the amount of input
DNA required (high compared with some other molecular
assays), and the labor-intensive and time-consuming nature of670a two-chemistry process. In the past decade, major advances in
massively parallel sequencing technologies will allow much
more comprehensive assessment of the full spectrum of
genomic alterations (eg, mutations, indels, copy number
changes, structural rearrangements, and epigenetic changes),
contributing to individual cancers. Initial reports that use such
technologies capable of reading multifaceted genomic infor-
mation in an efﬁcient, timely, and cost-effective manner have
found the utility of this approach for tumor mutation proﬁling
and individualized cancer treatment.26,27
Our study represents the ﬁrst large-scale, enterprise-level
application of the OncoMap platform for mutation proﬁling
of all types of cancer in a clinical laboratory. The proven
effect of using mutation assessment in the selection of
patients for targeted therapies (eg, in BRAF- and ALK-
inhibitor phase 1 trials9,62) reiterates the need for molecular
stratiﬁcation of patients with cancer. The results of our study
highlight several examples of informative oncogene muta-
tions missed by standard single-gene clinical assays and
describe a rational framework for enterprise-level tumor
proﬁling to be used as a standard means to guide patient
stratiﬁcation and enrollment for targeted cancer therapies.
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